- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | YSB (09885): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 24.03. | YSB (09885): VOLUNTARY ANNOUNCEMENT GRANT OF SHARE OPTIONS PURSUANT TO THE 2023 SHARE INCENTIVE PLAN | - | HKEx | ||
| YSB Aktie jetzt für 0€ handeln | |||||
| 23.03. | YSB (09885): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 23.03. | YSB (09885): UPDATES ON THE ACQUISITION OF THE TARGET COMPANY INVOLVING ISSUE OF CONSIDERATION SHARES UNDER GENERAL MANDATE | - | HKEx | ||
| 23.03. | YSB (09885): FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025 | 3 | HKEx | ||
| 23.03. | YSB Inc. Reveals Rise In Full Year Income | - | RTTNews | ||
| 23.03. | YSB (09885): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025 | 1 | HKEx | ||
| 11.03. | YSB (09885): NOTICE OF BOARD MEETING | - | HKEx | ||
| 10.02. | YSB (09885): GRANT OF SHARE AWARDS PURSUANT TO THE 2023 SHARE INCENTIVE PLAN | 1 | HKEx | ||
| 19.11.25 | YSB (09885): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 19.11.25 | YSB (09885): VOLUNTARY ANNOUNCEMENT SHARE REPURCHASE AND INCREASE IN SHAREHOLDING BY EXECUTIVE DIRECTOR | - | HKEx | ||
| 12.11.25 | YSB (09885): VOLUNTARY ANNOUNCEMENT SHARE REPURCHASE AND INCREASE IN SHAREHOLDING BY EXECUTIVE DIRECTOR | - | HKEx | ||
| 07.11.25 | YSB (09885): VOLUNTARY ANNOUNCEMENT SHARE REPURCHASE | - | HKEx | ||
| 06.11.25 | YSB (09885): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 06.11.25 | YSB (09885): VOLUNTARY ANNOUNCEMENT UNUSUAL MOVEMENTS IN THE PRICES AND TRADING VOLUME OF SHARES AND SHARE REPURCHASE AND INCREASE IN SHAREHOLDING BY ... | - | HKEx | ||
| 27.10.25 | YSB (09885): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 27.10.25 | YSB (09885): VOLUNTARY ANNOUNCEMENT SHARE REPURCHASE | - | HKEx | ||
| 15.10.25 | YSB (09885): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 15.10.25 | YSB (09885): VOLUNTARY ANNOUNCEMENT SHARE REPURCHASE | - | HKEx |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 40,120 | -0,82 % | Evotec holt früheren Bayer-Vorstand Weinand als Aufsichtsratschef | DJ Evotec holt früheren Bayer-Vorstand Weinand als Aufsichtsratschef
DOW JONES--Evotec bekommt einen neuen Aufsichtsratschef. Wie das im TecDAX und SDAX notierte Unternehmen mitteilte, wurde der... ► Artikel lesen | |
| DERMAPHARM | 43,950 | +2,09 % | EQS-PVR: Dermapharm Holding SE: Veröffentlichung über Erwerb oder Veräußerung eigener Aktien nach § 40 Abs. 1 Satz 2 WpHG | EQS Stimmrechtsmitteilung: Dermapharm Holding SE
Dermapharm Holding SE: Veröffentlichung über Erwerb oder Veräußerung eigener Aktien nach § 40 Abs. 1 Satz 2 WpHG
07.04.2026... ► Artikel lesen | |
| ZOETIS | 100,05 | -0,45 % | Zoetis Inc. to Acquire Animal Genomics Business from Neogen, Accelerating Precision Animal Health Innovation | Acquisition strengthens Zoetis' leadership in Precision Animal Health by integrating Neogen's global genomics capabilities, expanding predictive insights and individualized care worldwide
PARSIPPANY... ► Artikel lesen | |
| CSPC PHARMA | 0,998 | -0,63 % | CSPC PHARMA (01093): UPDATE ANNOUNCEMENT - CONNECTED TRANSACTION IN RELATION TO THE DISPOSAL OF 30.0704% EQUITY INTEREST IN THE TARGET COMPANY | ||
| FILANA THERAPEUTICS | 1,442 | +1,12 % | Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. | New corporate identity reflects the Company's mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading... ► Artikel lesen | |
| CANTOURAGE GROUP | 4,720 | +2,39 % | Original-Research: Cantourage Group SE (von NuWays AG): BUY | Original-Research: Cantourage Group SE - from NuWays AG
18.03.2026 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 4,100 | +0,99 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 64,12 | +0,83 % | RBC Capital startet Coverage für BridgeBio Pharma mit "Outperform" und Kursziel 100 US-Dollar | ||
| HIKMA PHARMACEUTICALS | 15,080 | -0,85 % | Hikma Pharmaceutical - Director/PDMR Shareholding | ||
| ORION | 72,70 | -0,34 % | Orion Oyj: Orion publishes Interim Report for January-March 2026 and holds a webcast on 23 April 2026 | ||
| ALK-ABELLO | 28,000 | -1,41 % | ALK Abello: Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff | ||
| ACLARIS THERAPEUTICS | 3,452 | +0,29 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis | - Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| OTSUKA HOLDINGS | 60,00 | +4,35 % | Biodexa Pharmaceuticals PLC: Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer | MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST)Meg Flippin, Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / February 19, 2026... ► Artikel lesen | |
| MIRUM PHARMACEUTICALS | 84,16 | +3,70 % | Cantor Fitzgerald reiterates Mirum Pharmaceuticals stock rating | ||
| CIPHER PHARMACEUTICALS | 11,600 | 0,00 % | Cipher Pharmaceuticals übertrifft Gewinnerwartungen, verfehlt aber Umsatzziel |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu YSB INC finden Sie auf Wallstreet Online.